Friday, 16 August 2013

QS inhibitor compounds offer potential for the treatment of P. aeruginosa infections

Main Category: MRSA / Drug Resistance
Article Date: 15 Aug 2013 - 1:00 PDT Current ratings for:
QS inhibitor compounds offer potential for the treatment of P. aeruginosa infections
not yet ratednot yet rated

The fight against antibiotic-resistant superbugs has taken a step forward thanks to a new discovery by scientists at The University of Nottingham.

A multi-disciplinary research team at the University's Centre for Biomolecular Sciences has uncovered a new way of inhibiting the toxicity and virulence of the notorious superbug, Pseudomonas aeruginosa.

This bacteria produces an armoury of virulence factors and is resistant to many conventional antibiotics. It is almost impossible to eradicate P. aeruginosa from the lungs of people with cystic fibrosis and is therefore a leading cause of death among sufferers. The bug also causes a wide range of infections particularly among hospital patients.

The new discovery concerns the bacterial cells' ability to 'talk' to each other by producing and sensing small chemical signal molecules. This is called 'quorum sensing' (QS) and enables a population of individual bacteria to act socially rather than as individuals. QS allows a population of bacteria to assess their numerical strength and make a decision only when the population is 'quorate'.

The mechanism through which QS signals work is by activating gene expression upon interaction of a QS signal molecule with a receptor protein. In many disease-causing bacteria, QS controls genes which are essential for infection. These genes code for virulence factors such as toxins which cause damage to host tissues and the immune system. Interfering with the QS signalling process blocks bacterial virulence and renders bacteria unable to cause infection. Consequently QS systems are molecular targets for the development of new anti-infective drugs which do not kill bacteria but instead block their ability to cause disease.

In a study published in the journal, PLOS Pathogens, the Nottingham team has described how they solved the 3D structure of a receptor protein called PqsR used by P. aeruginosa to sense alkyl quinolone QS signal molecules so that they could visualize the shape of the QS signal molecule-binding site within the PqsR protein.

Professor of Molecular Microbiology, Paul Williams, said: "We were able to synthesize and screen a library of chemical compounds which could fit within the PqsR binding site and block receptor activation by the QS signal molecules. The active compounds were screened for their ability to inhibit QS and through a process of chemical refinement some novel potent QS inhibitors were discovered which were tested biologically on P.aeruginosa and shown to block virulence gene expression."

Professor of Macromolecular Crystallography, Jonas Emsley, added: "This ground-breaking work establishes a platform for the future evaluation and further development of these new QS inhibitor compounds as potential drugs for the treatment of P. aeruginosa infections."

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our mrsa / drug resistance section for the latest news on this subject.

Ilangovan A, Fletcher M, Rampioni G, Pustelny C, Rumbaugh K, et al. (2013) "Structural Basis for Native Agonist and Synthetic Inhibitor Recognition by the Pseudomonas aeruginosa Quorum Sensing Regulator PqsR (MvfR)" PLoS Pathog 9(7): e1003508. doi:10.1371/journal.ppat.1003508

The research was funded by the Biotechnology and Biological Sciences Research Council (BBSRC).

University of Nottingham

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

University of Nottingham. "QS inhibitor compounds offer potential for the treatment of P. aeruginosa infections." Medical News Today. MediLexicon, Intl., 15 Aug. 2013. Web.
15 Aug. 2013. APA

Please note: If no author information is provided, the source is cited instead.


'QS inhibitor compounds offer potential for the treatment of P. aeruginosa infections'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam). We reserve the right to amend opinions where we deem necessary.

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

No comments:

Post a Comment